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Genetic predisposition for childhood cancer is under diagnosed. Identifying these patients may lead to
therapy adjustments in case of syndrome-related increased toxicity or resistant disease and syndrome-
speciﬁc screening programs may lead to early detection of a further independent malignancy. Cancer
surveillance might also be warranted for affected relatives and detection of a genetic mutation can allow
for reproductive counseling.
Here we present an easy-to-use selection tool, based on a systematic review of pediatric cancer
predisposing syndromes, to identify patients who may beneﬁt from genetic counseling. The selection
tool involves ﬁve questions concerning family history, the type of malignancy, multiple primary ma-
lignancies, speciﬁc features and excessive toxicity, which results in the selection of those patients that
may beneﬁt from referral to a clinical geneticist.
© 2016 The Authors. Published by Elsevier Masson SAS. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
In literature on this topic, it is often mentioned that 10% of pe-
diatric cancer results from genetic predisposition. This number is
derived from a study by Narod and colleagues in 1991 who per-
formed a cancer registry and literature review (Narod et al., 1991).
Since 1991, many novel genes predisposing to pediatric cancer have
been reported. Examples are germline SMARCB1 mutations in pa-
tients with malignant rhabdoid tumors and SUFU mutations pre-
disposing to medulloblastoma (Taylor et al., 2002; Versteege et al.,
1998).
Identifying susceptibility for childhood cancer is relevant for the
patient and his family. For some patients, this may lead to modiﬁed
treatment strategies in case of expected increased toxicity or
resistant disease as well as surveillance measures for early detec-
tion of a further independent malignancy. Family members ofRadboud University Medical
he Netherlands.
.nl (M.C.J. Jongmans).
Masson SAS. This is an open accesspatients with an identiﬁed cancer predisposition syndrome may
beneﬁt from knowledge on increased cancer risks for themselves
and also for them a cancer surveillance program might be war-
ranted. Furthermore, detection of a cancer predisposing genetic
mutation gives opportunities for reproductive counseling and
prenatal diagnosis. Finally, identifying a genetic cause simply an-
swers the question many parents presumably ask themselves:
“Why did my child get cancer?”
Although the signiﬁcance of recognizing tumor susceptibility in
children is evident, in daily practice underlying syndromes and
positive family histories are easily missed (Knapke et al., 2012;
Merks et al., 2005). Recognizing susceptibility for pediatric cancer
is further complicated by the fact that mutations in cancer pre-
disposing genes do not necessarily result in a recognizable clinical
phenotype. In addition, genetic forms of childhood cancer often
lack a clear family history, for instance due to small family size or
because the malignancy has arisen due to recessive or de novo
germline mutations. Moreover, historically, pediatric cancer is a
highly lethal disease and affected children did not grow up to start a
family and pass on the predisposing mutation.
An easy-to-use selection tool to identify patients at high risk forarticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
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disposition in pediatric cancer patients. Here we describe the se-
lection tool that we have developed and we give a review of the
literature on which the tool is based.
2. Tool development
A review of the literature on pediatric cancer predisposition
syndromes resulted in ﬁve characteristics on which we have based
our selection tool: family history, speciﬁc malignancies, multiple
primary cancers, speciﬁc features and excessive toxicity. Knowl-
edge of those ﬁve characteristics can help to select patients at high
risk for genetic predisposition, and identify who may beneﬁt
from referral to a clinical geneticist for further evaluation. (Fig. 1,
the tool is also available in the supplemental ﬁle as a PDF that can
be used in daily clinic and on https://www.radboudumc.nl/Pages/
hereditarycancer.aspx).
2.1. Family history of pediatric and adult cancers
The most well known feature of hereditary cancer is clustering
of cancer in a family. Most parents and physicians are aware of
possible genetic predisposition if several childrenwithin one family
are affected by cancer, particularly if this regards a similar type of
cancer. An example is clustering of neuroblastoma in families with
an ALK germline mutation (Mosse et al., 2008).
The combination of pediatric and adult cancer at relatively
young age in one family and combinations of different types of
cancer should also trigger awareness of cancer susceptibility. Li
Fraumeni syndrome, for instance, predisposes for a wide range of
malignancies, with particularly high occurrences of soft tissue and
bone sarcomas, brain tumors and breast cancer. Cancer in Li Frau-
meni syndrome affects children, adolescents and adults.
Autosomal dominant syndromes comprise the majority of
conditions that convey an increased risk of cancer at adult age.
Several childhood cancer predisposing syndromes, which each
individually are rare, show recessive inheritance. Consanguinity
increases the birth prevalence of individuals with recessive disor-
ders. Therefore, it is important to ask about family connections
among the parents of the affected child.
In the selection tool (Fig. 1), family history-based criteria are
mentioned for selection of patients with possible genetic predis-
position for childhood cancer. The age of onset cut-off of 45 years
for the selection criterion ‘multiple affected relatives' was chosen to
avoid referral of a large number of families affected by common
cancers diagnosed after age 50 such as breast cancer.
2.2. Children with speciﬁc malignancies
Several malignancies have such a strong association with ge-
netic predisposition, that diagnosis of these cancers always merits
genetic evaluation independent of family history or other factors.
Those malignancies are summarized in Table 1 and can be divided
in two subgroups: malignancies that are regularly encountered in
adult patients, but are extremely rare in children (for instance
colorectal cancer due to constitutional mismatch repair deﬁciency
syndrome (Wimmer and Etzler, 2008)) and childhoodmalignancies
highly correlated with one or more speciﬁc genetic syndromes (for
instance choroid plexus carcinoma and Li Fraumeni syndrome
(Krutilkova et al., 2005)). When we composed this list of malig-
nancies, we selected on the strength of the association with a
predisposing condition, although exact numbers are often unavai-
lable. In addition, we considered whether the syndrome is recog-
nizable by other features included in our referral test. For instance,
many syndromes have been reported in association with Wilmstumor but most of these can be recognized by additional features,
like congenital anomalies or overgrowth (Scott et al., 2006). To
avoid referral of all children with Wilms tumor, including the
children at very low probability of a genetic condition, we did not
include this malignancy as a referral criterion.2.3. Children affected by multiple primary tumors
If a child develops two or more synchronous or metachronous
neoplasms, genetic predisposition needs to be taken into account.
Important in this respect is that children who seem to have a
relapse of their ﬁrst malignancy, may actually suffer from a second
primary malignancy, that is similar to the original disease
(Szczepanski et al., 2011).
Another complicating factor in patients with multiple consec-
utive neoplasms is that consecutive malignancies can have a
treatment-related origin rather than being a result of genetic pre-
disposition, or can be caused by a combination of both. This may be
encountered more and more frequently, because the treatment of
childhood cancer has tremendously improved over the past several
decades, resulting in a large and growing population of long-term
survivors. In general, the secondary treatment related malig-
nancies are of twomain types: acute leukemia andmyelodysplastic
syndrome after chemotherapy, or solid tumors related to radio-
therapy (Bhatia and Sklar, 2002). An example of the latter type is a
susceptibility for breast cancer in women treated with chest radi-
ation for pediatric Hodgkin lymphoma (Travis et al., 2005). Other
well-established radiation-related solid malignant neoplasms
include thyroid cancers, brain tumors and sarcomas (Bhatia and
Sklar, 2002). The individual role of chemotherapeutic agents is
more difﬁcult to determine, as most children receive multiple
agents. An evident association has been found for topoisomerase II
inhibitors and alkylating agents and the development of secondary
acute myeloid leukemia (Bhatia and Sklar, 2002). The cumulative
dose of these agents is an important factor in the actual risk of
developing a secondary malignancy.
The timeframe separating the two malignancies can be infor-
mative to distinguish between therapy related and genetic pre-
disposition related cancers. The latency between treatment of the
primary cancer and the development of a secondary
chemotherapy-related leukemia is generally short (~3 years),
whereas solid, radiation induced tumors seem to have a latency
longer than ten years (Bhatia and Sklar, 2002). As a consequence,
genetic cancer predisposition needs to be considered in patients
having multiple solid tumors in rapid succession or in patients who
develop a second solid tumor without a history of radiotherapy or a
second leukemia without a previous chemotherapy treatment.
To conclude: any child with two malignancies should be
referred unless the second malignancy is consistent in time and/or
tissue type with those expected from their treatment regimen.2.4. Children with cancer and speciﬁc features
To facilitate the recognition of patients that need referral to a
clinical geneticist, we here provide an overview in which the
currently known childhood cancer predisposing syndromes are
primarily categorized based on their phenotypic presentation.
Many childhood cancer predisposing syndromes have characteris-
tics in common. These are symptoms unrelated to the malignancy,
which are present at birth or develop throughout life and range for
instance from benign and subtle skin lesions to life threatening
hematological conditions. We have divided these features in seven
subgroups (Table 2) that will be explained in this section.
Fig. 1. Tool to select children with cancer who may beneﬁt from referral to a clinical geneticist. The selection tool is also available in the supplemental ﬁle as a PDF that can be used
in daily clinic and on https://www.radboudumc.nl/Pages/hereditarycancer.aspx.
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Many molecular defects are known to give rise to congenital
anomalies and cancer. Many molecular pathways involved in can-
cer initiation also play an important role in embryonic develop-
ment. Numerous studies have demonstrated an increased
incidence of congenital anomalies in children with cancer (Narod
et al., 1997; Merks et al., 2008). However, in all studies the
numbers were too small to determine any signiﬁcant correlation
between tumor types and individual anomalies.
This is illustrated by the relation between oral cleft and cancer
development. Several cancer syndromes predispose children to a
cleft lip and/or palate. Approximately eight percent of patients with
Gorlin syndrome have an oral cleft (Lambrecht and Kreusch, 1997),
and also in children with Beckwith Wiedemann syndrome and
patients with a CDH1 mutation predisposing to gastric cancer and
lobular breast cancer, this is a rarely reported feature (Choufani
et al., 2010; Frebourg et al., 2006). Cohort studies however pro-
vide no evidence for an increased overall cancer risk for individuals
bornwith oral clefts (Bille et al., 2005; Blot et al., 1980). Apparently,
the incidence of oral cleft associated tumor predisposition syn-
dromes, and the co-occurrence of oral cleft and cancer in patients
with these syndromes is too low to give a signiﬁcant correlation
within such large population based studies. Nonetheless, if a child
develops cancer and has an oral cleft or another congenital mal-
formation, a cancer predisposing syndrome needs to be considered.
2.4.2. Facial dysmorphisms
Facial appearance can be a signiﬁcant clue in the identiﬁcation
of syndromes. Children with the same syndrome often share
characteristic facial features at signiﬁcantly higher prevalence than
a control population. These facial features can be subtle, as for
example in Noonan syndrome (Fig. 2).
Pediatric oncologists are not speciﬁcally trained in recognizing
and describing dysmorphisms by standardized terms. However,
cancer predisposing syndromes characterized by dysmorphisms
without any other features are extremely rare and therefore most
children will still be selected based on other criteria of the tool in
case dysmorphisms are not recognized by the oncologist.
2.4.3. Intellectual disability
Studies that address the prevalence rate of intellectual disability
(ID) among childhood cancer patients are not available. Such a
study would be complicated by the fact that the development of
children may be affected directly by a malignancy, for instance in
children with a brain tumor, by the patient being chronically ill, as
well as by the treatment for cancer. Therefore, while assessing the
level of intelligence, one has to inquire for the developmental skills
prior to diagnosis of cancer.
Among the causes of cancer predisposing syndromes presenting
with ID, two groups of genetic defects can be distinguished.
Monogenic aberrations that give rise to both ID and cancer, and
chromosomal aberrations, which affect a combination of a cancer
predisposing gene and an ID gene. The latter aberrations include
trisomies, monosomies, unbalanced translocations and (submi-
croscopic) deletions and duplications. These chromosomal rear-
rangements have been useful for the localization of relevant cancer
genes: the RB1 gene, implicated in retinoblastoma (Francke and
Kung, 1976; Friend et al., 1986), and APC, responsible for familial
adenomatous polyposis (Groden et al., 1991; Herrera et al., 1986;
Kinzler et al., 1991) were mapped following the report of patients
with ID, dysmorphic facial features and cancer.
2.4.4. Overgrowth
Childhood overgrowth syndromes are often associated with an
increased risk of cancer, particularly embryonic tumors (Table 3).An overgrowth syndrome is deﬁned as a condition with either
localized or generalized excessive growth for age and sex.
Congenital overgrowth is deﬁned by a neonatal weight above the
97th percentile, while in childhood and adulthood overgrowth is
deﬁned by height rather than by weight. Many of the overgrowth
disorders present with excessive growth in fetal life and infancy
with subsequent decline in growth rate such that adults often have
normal growth parameters. The most frequent overgrowth disor-
der is Beckwith Wiedemann syndrome, characterized by a large
tongue, macrosomia, midline abdominal wall defects, ear creases or
pits and neonatal hypoglycemia (Choufani et al., 2010).
2.4.5. Growth failure
Growth retardation, like overgrowth, is an important hallmark
of various pediatric cancer predisposing syndromes. These syn-
dromes are mostly caused by mutations in DNA repair genes, mu-
tations in RAS pathway genes or chromosomal aberrations
(Table 4). Since cancer treatment can result in growth delay in
children, it is important to collect data on the growth of the child
before cancer diagnosis. The degree of growth retardation varies
between the different syndromes. Some children have growth
measures within the normal range for their age and gender, but are
short compared to their target height. This is frequently observed in
children with Noonan syndrome, which is further characterized by
mild facial dysmorphisms and congenital heart defects.
2.4.6. Skin lesions
In many tumor predisposition syndromes, cutaneous ﬁndings
are the presenting symptoms (Karalis et al., 2011). Some skin fea-
tures manifest in speciﬁc periods of life. The mucocutaneous hy-
perpigmentation in Peutz-Jeghers syndrome for instance, fades
after puberty (Beggs et al., 2010) and neuroﬁbromas in Neuroﬁ-
bromatosis type 1 generally appear not until late childhood or adult
age. Therefore, in order to recognize autosomal dominant syn-
dromes, examination of the skin of both parents can be helpful. The
observation of palmar pits in a parent of a child with medullo-
blastoma, is suggestive of Gorlin syndrome (Lo, 2008). Other skin
lesions are striking for their appearance early in life. In Xeroderma
pigmentosum, marked freckling of the face is present before the
age of two years, which is rarely seen in children (Lehmann et al.,
2011).
Cafe-au-lait macules are the most frequent cutaneous mani-
festation of tumor predisposition. Solitary cafe-au-lait spots are
common birthmarks. The presence of more than one cafe-au-lait
spot is less common. In school-aged children, at least one cafe-au-
lait spot is noted in approximately 25% of children, whereas three or
more macules are observed in 1e3% of the children (Shah, 2010). It
is unusual for sporadic cafe-au-lait spots to develop after the age of
six years; in syndromes such as Neuroﬁbromatosis type 1, however,
new macules may continue to develop throughout childhood and
adulthood (Shah, 2010). Speciﬁc physical investigation using wood
light can be of assistance to improve observation of hyper-as well as
hypopigmentated skin lesions. The latter can be a hallmark of
constitutional mismatch repair deﬁciency syndrome for instance.
In Table 5 skin lesions associated with childhood cancer pre-
disposing syndromes are summarized.
2.4.7. Hematological abnormalities
In several syndromes, defects in hematopoiesis precede cancer
development, including abnormalities of a single cell lineage or
pancytopenia. Many of these syndromes predispose to leukemia,
primarily acute myeloid leukemia and/or myelodysplastic syn-
drome. Solid tumors occur in Fanconi anemia, dyskeratosis con-
genita and Diamond Blackfan anemia. (Alter, 2007) Table 6 gives an
overview of tumor predisposition syndromes affecting
Table 1
Cancer types considered eligible for clinical genetic evaluation.
1) Cancers of adult age, which are extremely rare in the pediatric age group
i.e. colorectal cancer, ovarian cancer, pheochromocytoma, basal cell carcinoma etc.
2) Tumors highly correlated with
speciﬁc syndrome(s)
Syndrome Ref.
Adrenocortical carcinoma Li Fraumeni syndrome, BWS, MEN1, FAP (Else, 2012)
Atyp. teratoid malignant rhabdoid tumor Rhabdoid Predisposition syndrome (Bourdeaut et al., 2011)
Cerebellar gangliocytoma PTEN hamartoma tumor syndrome (Padberg et al., 1991)
Choroid Plexus Carcinoma Li Fraumeni syndrome (Krutilkova et al., 2005)
Endolymphatic sac tumors Von Hippel-Lindau syndrome (Maher et al., 2011)
Hemangioblastoma Von Hippel-Lindau syndrome (Maher et al., 2011)
Hepatoblastoma FAP, BWS (Giardiello et al., 1996; Hughes and Michels, 1992;
Rump et al., 2005)
Juvenile myelomonocytic leukemia Neuroﬁbromatosis type 1, Noonan syndrome, CBL germline syndrome,
Constitutional Mosaic Trisomy 8
(Loh, 2011; Ripperger et al., 2011)
Low hypodiploid acute lymphoblastic
leukemia
Li Fraumeni syndrome (Holmfeldt et al., 2013)
Malignant peripheral nerve sheath tumor Neuroﬁbromatosis type 1 (Friedrich et al., 2007; McCaughan et al., 2007)
(Malignant) Schwannoma Neuroﬁbromatosis type 1 and 2, Schwannomatosis, Carney complex (Rodriguez et al., 2012)
Medullary thyroid carcinoma MEN2 (Marini et al., 2006)
Medulloblastoma (in particular < 3 years
of age)
FAP, Gorlin syndrome, germline mutations in SUFU (Attard et al., 2007; Evans et al., 1991a; Slade et al.,
2011a)
Optic pathway glioma Neuroﬁbromatosis type 1 (Rosser and Packer, 2002)
Ovarian Sertoli-Leydig cell tumor DICER1 syndrome (Slade et al., 2011b)
Pleuropulmonary blastoma DICER1 syndrome (Hill et al., 2009)
Pineoblastoma DICER1 syndrome (De Kock et al., 2014a)
Pituitary blastoma DICER1 syndrome (De Kock et al., 2014b)
Retinoblastoma Retinoblastoma predisposition syndrome (Aerts et al., 2006)
BWS ¼ Beckwith Wiedemann syndroom; FAP ¼ Familial Adenomatous Polyposis
Table 2
Patient characteristics suggestive of hereditary pediatric
cancer.
1 Congenital anomalies
2 Facial dysmorphisms
3 Intellectual disability
4 Growth disturbances
5 Skin lesions
6 Hematological disorders
7 Immune deﬁciency
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plantation is the treatment of choice. Great care should be given to
ensure that a non affected family member will be selected as donor.
Therefore, recognition of these syndromes is of prime importance.Fig. 2. A boy with Noonan syndrome caused by a PTPN11 mutation. Note a bilateral
downslant of the palpebral ﬁssures, ptosis, a broad nasal bridge and low set posteriorly
rotated ears.2.4.8. Immunodeﬁciencies
Children with primary immunodeﬁciencies are at risk for
developing cancer, particularly lymphoproliferative disorders. In
the majority of these conditions, infections play a pivotal role in the
development of lymphomas and carcinomas. In addition, the defect
in immune surveillance may affect the ability to identify and
eliminate cancer cells (Tran et al., 2008). An example is Wis-
kotteAldrich syndrome, characterized by eczema, thrombocyto-
penia, immune deﬁciency, and a high risk (13e22%) of developing
lymphomas (Sullivan et al., 1994; Imai et al., 2004).
A separate group of immunodeﬁciency syndromes are the ge-
netic disorders of DNA repair. The development of effective im-
mune responses is dependent on the generation of an enormous
number of genetically diverse B and T cells (Oltz, 2001). These
unique cells are created by breaking, randomly re-sorting and then
joining the DNA sequences coding for antigen receptors. For this
process the DNA repair mechanisms normally utilized to maintain
genome stability are used (Gennery et al., 2000). As a result, defects
in these pathways result both in cancer, mainly tumors of he-
matopoietic and epithelial origin, and in immunodeﬁciency. A re-
view of immunodeﬁciency conditions in children is provided in
references (Adriaensen et al., 2009) and (Ochs and Hagin, 2014).2.5. Children with excessive treatment toxicity
Most treatments for cancer give adverse side effects and a
proportion of patients will experience signiﬁcant complications. In
some cancer predisposition syndromes, however, the side effects
are more severe, which may give a clue for syndrome diagnosis.
Examples of excessive treatment toxicity are seen in Ataxia Telan-
giectasia, Nijmegen Breakage syndrome, and other immunodeﬁ-
ciency and DNA repair disorders. Patients suffering from these
syndromes may experience severe complications after standard
doses of radiotherapy or chemotherapy, resulting from defective
repair of normal tissues following therapy (Bienemann et al., 2011).
In some syndromes, the adverse side effects are not present
during the treatment, but become apparent after a time interval.
Table 3
Overgrowth syndromes predisposing to cancer.
Syndrome Malignancies reported Ref.
Generalized overgrowth syndromes
Beckwith Wiedemann syndrome Wilms tumor, hepatoblastoma, adrenocortical carcinoma, neuroblastoma,
rhabdomyosarcoma
(Rump et al., 2005)
Sotos syndrome Leukemia, lymphoma, Wilm's tumor, sacrococcygeal teratoma, neuroblastoma (Tatton-Brown and Rahman, 2007)
Simpson Golabi Behmel syndrome Wilms tumor, hepatoblastoma, neuroblastoma, gonadoblastoma, hepatocellular
carcinoma
(Lapunzina et al., 1998)
Perlman syndrome Wilms tumor (Alessandri et al., 2008)
Weaver syndrome Neuroblastoma (Basel-Vanagaite, 2010)
Partial overgrowth syndromes
Isolated Hemihyperplasia Wilms tumor, hepatoblastoma, adrenocortical carcinoma (Bliek et al., 2008; Clericuzio and Martin,
2009)
Macrocephaly-capillary malformation
syndrome
Leukemia, meningioma, retinoblastoma, Wilms tumor (Lapunzina et al., 2004)
Proteus syndrome Various, but rare (Gordon et al., 1995)
PIK3CA-Related Segmental Overgrowth Wilms tumor, meningeoma (Mirzaa et al., 2013)
Macrocephaly syndromes
PTEN hamartoma tumor syndrome Cerebellar gangliocytoma, thyroid cancer, breast cancer, endometrial cancer, colon
cancer
(Nieuwenhuis et al., 2014)
Neuroﬁbromatosis type 1 Optic pathway glioma, leukemia, malignant peripheral nerve sheath tumor (Walker et al., 2006)
Costello syndrome Rhabdomyosarcoma, neuroblastoma, bladder cancer (Kratz et al., 2011; Gripp, 2005; Kratz et al.,
2015)
Gorlin syndrome Medulloblastoma, basal cell carcinoma (Evans et al., 1991a; Jones et al., 2011)
Tall stature
MEN 2B Medullary thyroid carcinoma, phaeochromocytoma (Skinner et al., 1996)
* various epigenetic and/or genetic alterations that deregulate imprinted genes on chromosome 11p15.5.
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tion therapy, and may develop a large number of basal cell tumors
in the irradiated area several years after exposure (Evans et al.,
1991b; Kimonis et al., 1997; Walter et al., 1997). This example il-
lustrates the importance of considering the presence of a syndrome
before starting treatment.3. Discussion
In this article, an overview of symptoms and characteristics is
given for the identiﬁcation of children affected by cancer who are atTable 4
Growth retardation syndromes predisposing to cancer.
Growth retardation
syndromes
Low birth-
weight
Short
stature
Micro-
cephaly
Malignancies report
DNA repair syndromes
Mosaic Variegated Aneuploidy þ þ þ Wilms tumor, rhabd
Fanconi anemia ~5% þ ~20% MDS, AML, ALL, squa
and anogenital regio
Rothmund Thomson
syndrome
þ þ e Osteosarcoma, skin
Cartilage Hair Hypoplasia þ þ e Lymphoma, basal ce
Bloom syndrome þ þ þ AML, lymphoma, ep
Nijmegen Breakage syndrome þ þ þ Lymphoma, medullo
Ras related disorders
Cardio Facio Cutaneous
syndrome
e þ/ e leukemia, lymphom
Costello syndrome e þ e Rhabdomyosarcoma
Noonan syndrome e þ e Leukemia, neuroblas
Noonan syndrome with
multiple lentigines
e <50% e Leukemia, neuroblas
Chromosomal aberrations
Trisomy 21 þ/ þ þ Leukemia
(Mosaic) Trisomy 18 þ þ þ Hepatoblastoma
Turner syndrome þ þ e Gonadoblastoma
Other
Rubinstein Taybi syndrome e þ þ Various
Mulibrey Nanism þ þ e Wilms tumorhigh risk of carrying a cancer predisposing genetic mutation. Based
on these criteria we have developed a selection tool, to be used by
the pediatric oncologist for the selection of children who may
beneﬁt from referral to a clinical geneticist. To explain howwe have
chosen the different items on which we have based the selection
tool, many examples of cancer prone syndromes and their associ-
ated features are given. We would like to state however, that this
manuscript does not provide a complete list of all pediatric cancer
predisposing conditions and associated symptoms.
Previously, in our center online selection tools were developed
to detect patients with a high familial risk of colorectal cancer anded Ref.
omyosarcoma (Jacquemont et al., 2002)
mous cell carcinomas of the head, neck
n
(Alter, 2003)
cancer (Wang et al., 2001)
ll carcinoma (Taskinen et al., 2008)
ithelial cancers (German, 1997)
blastoma, glioma, rhabdomyosarcoma (Wegner et al., 1999)
a (Kratz et al., 2011; Kratz et al., 2015)
, neuroblastoma, bladder cancer (Kratz et al., 2011; Gripp, 2005; Kratz et al.,
2015)
toma, rhabdomyosarcoma (Kratz et al., 2011; Kratz et al., 2015;
Jongmans et al., 2011)
toma (Kratz et al., 2011)
(Khan et al., 2011)
(Maruyama et al., 2001)
(Bianco et al., 2009)
(Miller and Rubinstein, 1995)
(Karlberg et al., 2009)
Table 5
Cutaneous features of childhood cancer predisposition syndromes.
Skin lesions Syndrome
Abnormal pigmen-
tation
Cafe-au-lait spots CMMR-D, NF-1, NF-2, Legius syndrome, Fanconi anemia, Ataxia telangiectasia, Carney complex,
MEN1, Bloom syndrome
Hypopigmented macules Fanconi anemia, CMMR-D, Tuberous Sclerosis, Bloom syndrome
Axillary freckling NF-1, Legius syndrome
Pigmented macules on mucosal surfaces, face, ﬁngers
and peri-anal.
Peutz-Jeghers syndrome
Marked freckling of sun-exposed areas Xeroderma pigmentosum
Lentigenes Noonan syndrome with multiple lentigines, Carney complex
Reticular pigmentation Dyskeratosis Congenita
Epidermal naevi PIK3CA-Related Segmental Overgrowth
Vascular changes Cutaneous hemangiomas Beckwith Wiedemann syndrome, PIK3CA-Related Segmental Overgrowth
Angioﬁbromas MEN1, Tuberous Sclerosis
Telangiectasias Ataxia Telangiectasia, Bloom syndrome
Capillary malformations PIK3CA-Related Segmental Overgrowth
Facial naevus ﬂammeus Beckwith Wiedemann syndrome, PIK3CA-Related Segmental Overgrowth
Photo sensitivity Sun-sensitive butterﬂy facial rash Bloom syndrome, Rothmund Thomson syndrome
Severe sun-sensitivity Xeroderma pigmentosum
Poikiloderma Xeroderma pigmentosum, Rothmund Thomson syndrome, Ataxia telangiectasia
Skin tumors Mucosal neuromas MEN2B
Cutaneous neuromas MEN2A
Lipomas MEN1, PIK3CA-Related Segmental Overgrowth
Neuroﬁbromas NF-1, Legius syndrome, CMMR-D
Schwannomas NF-1, Legius syndrome
Papillomatous papules Costello syndrome, PTEN hamartoma tumor syndrome
Cutaneous myxomas Carney complex
Acral keratoses Rothmund Thomson syndrome, PTEN hamartoma tumor syndrome
Trichilemmomas PTEN hamartoma tumor syndrome
Pilomatricomas CMMR-D
Other Facial milia Gorlin syndrome
Scleroderma-like skin changes Werner syndrome
Premalignant actinic keratoses Xeroderma pigmentosum
Seborrheic dermatitis Ataxia telangiectasia
Sebaceous and dermoid cysts Gorlin syndrome
Shagreen patch Tuberous Sclerosis
Palmar or plantar pits Gorlin syndrome
Plantar hyperkeratosis Rothmund Thomson syndrome
Eczema Wiskott Aldrich syndrome, Ataxia telangiectasia
Blue naevi Carney complex
Generalized warts GATA2 deﬁciency
CMMR-D ¼ Constitutional mismatch repair-deﬁciency syndrome; NF-1 ¼ Neuroﬁbromatosis type I; NF-2 ¼ Neuroﬁbromatosis type II; MEN ¼multiple endocrine neoplasia.
M.C.J. Jongmans et al. / European Journal of Medical Genetics 59 (2016) 116e125122breast cancer. These tests guide clinicians and patients through
appropriate family history collection and provide an instant
conclusion regarding the presence or absence of an increasedTable 6
Cancer predisposition syndromes associated with preceding hematological abnormalitie
Condition Cell lineage Malignanc
Congenital amegakaryocytic
thrombocytopenia
All lineages MDS, leuk
Schwachmann Diamond
syndrome
All lineages MDS, AML
Fanconi anemia All lineages MDS, AML
head, neck
Dyskeratosis congenita All lineages Squamous
anogenita
Familial mosaic monosomy 7
syndrome
All lineages MDS, AML
Diamond Blackfan anemia Anemia AML, MDS
Cartilage hair hypoplasia Anemia, lymphopenia, neutropenia Lymphom
Familial platelet disorder with
predisp. for AML
Thrombocytopenia MDS, AML
Wiskott-Aldrich syndrome Thrombocytopenia, neutropenia Leukemia,
Severe congenital neutropenia Neutropenia MDS, leuk
ETV6 related familial leukemia Thrombocytopenia and red cell
macrocytosis
ALL
GATA2 deﬁciency Neutropenia, depletion of dendritic cells,
monocytes, B and NK cells
MDS, AML
ANKRD26-related
thrombocytopenia
Trombocytopenia MDS, AMLhereditary cancer risk (https://www.radboudumc.nl/pages/
hereditarycancer.aspx). Evaluation of the colorectal cancer
referral test revealed a high sensitivity in detecting individuals withs.
ies reported Ref.
emia (Geddis, 2011)
(Maserati et al., 2009)
, ALL, squamous cell carcinomas of the
and anogenital region
(Alter, 2003)
cell carcinomas of the head, neck and
l region
(Alter et al., 2009)
(Morrissette et al., 2010)
, osteosarcoma (Vlachos et al., 2012)
a, basal cell carcinoma (Taskinen et al., 2008)
, ALL (Owen et al., 2008)
lymphoma (Sullivan et al., 1994; Imai et al., 2004)
emia (Carlsson et al., 2012)
(Noetzli et al., 2015; Zhang et al.,
2015)
, HPV associated skin and cervical cancer (Hahn et al., 2011; Dickinson et al.,
2011; Hsu et al., 2011)
(Noris et al., 2013)
M.C.J. Jongmans et al. / European Journal of Medical Genetics 59 (2016) 116e125 123increased risk of Lynch syndrome, even if used by nonmedical staff
members (Dekker et al., 2014). The success of this selection tool
enthused us to develop something similar for children with pedi-
atric cancer, which of course is a much more heterogeneous group
of conditions.
The selection tool presented here has several limitations. The
input in the test is based on the physical examination, the medical
history and the pedigree evaluation performed by the pediatric
oncologist. Many studies have demonstrated poor family history
data in medical records (Wood et al., 2014). The test in itself may
already improve this part of clinical care for children with cancer
because it reminds physicians of collecting a family history. How-
ever, along with implementing this test in routine clinical care it is
essential to educate users of the test in the essentials of collecting a
thorough family history and what questions can be asked specif-
ically. The same is true for the physical examination by which
congenital anomalies, skin lesions and dysmorphisms are detected.
Educational sessions using pictures of recognizable features, or a
period of training alongside a clinical geneticist in daily practice
may improve the skills of the pediatric oncologist and thereby the
sensitivity of the test.
Another limitation of the test is a lack of evidence based studies
to support decisions about which criteria to include. Regarding
topics for which scientiﬁc literature was lacking, choices were
made based on experience and expertise of the authors. Validation
of the test at larger scale will reveal whether adjustments need to
be made.
We would like to make it abundantly clear that the guidelines
described are meant for genetics referral of a child already diag-
nosed with cancer and the test should not be used for consideration
of a cancer susceptibility syndrome in a child without a cancer
diagnosis. Although there are a number of cancer predisposing
disorders with for instance growth failure or intellectual disability
there are many more genetic conditions associated with these
features that do not have a substantial cancer risk. In addition, it is
important to realize that molecular genetic testing will not be
indicated in all children picked-out by the selection tool. The tool
helps to select children who may beneﬁt from referral to a clinical
geneticist and the geneticist will apply a further selection and will
decide in which patients molecular testing is indicated.
In conclusion, we have developed an easy-to-use selection tool,
based on a systematic review of pediatric cancer predisposing
syndromes, to select patients who may beneﬁt from genetic
counseling. We believe that structural application of the selection
tool for each newly diagnosed child with cancer will augment the
detection of children with a genetic predisposition for cancer.
Future studies are needed to reveal the sensitivity and speciﬁcity of
this tool.
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